EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY (ALERT-TBIx)

Banyan International

Status: Completed

Conditions: Traumatic Brain Injury

Treatments: Other: Blood draw within 12 hours of head injury

Study type: Observational

Funder types: Industry; Other U.S. Federal agency

Identifiers

NCT02439736

ATO-06x

Details and patient eligibility

About

The primary objective of this study is to evaluate Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of CT-positive subjects (as determined by an independent Neuroimaging Review Committee) presenting acutely with traumatic brain injury (Glasgow Coma Scale score 9-15).

Enrollment: 119 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The Subject is at least 18 years of age at screening.
• The Subject has presented to a Health Care Facility (HCF) or Emergency Department (ED) with a suspected traumatically induced head injury, as a result of insult to the head from an external force.
• A Glasgow Coma Scale score of 9-15 at the time of Informed Consent.
• The subject is CT-positive for acute intracranial lesion(s) based on the local neuroradiologist's review of the subject's head CT scan.
• The CT scan and CT report used to determine eligibility must be available.
• The blood sample is collected as close to the time of head injury as possible, but no later than 12 hours.
• The Subject or their legal representative is willing to undergo the Informed Consent process prior to enrollment into this study

Exclusion criteria

• Participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study would be acceptable).
• Time of injury cannot be determined.
• Primary diagnosis of ischemic or hemorrhagic stroke.
• Venipuncture not feasible (i.e., skin integrity compromised at the venipuncture sites, blood vessel calcification (i.e., IV drug users, advanced atherosclerosis) both upper limbs missing (congenital or amputee)).
• The subject has a neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
• The subject has a history of neurosurgery within the last 30 days.
• Administration of blood transfusion after head injury and prior to the study blood draw.
• The subject is a female who is pregnant or lactating.
• The Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation. If this criterion applies, a reason must be provided

Trial design

119 participants in 1 patient group

CT positive for acute intracranial lesion

Treatment:

Other: Blood draw within 12 hours of head injury